Qbiotics, page-740

From the Guardian.co.uk

Two of the first human patients to be treated with a revolutionary therapy that engineers immune cells to target specific types of cancer still possess cancer-killing cells a decade later with no sign of their illness returning.The finding suggests CAR T-cell therapy constitutes a “cure” for certain blood cancers, although adapting it to treat solid tumours is proving more challenging.
CAR – chimeric antigen receptor – T-cell therapy works by genetically engineering an individual’s T-cells to recognise and destroy cancer cells.

'Good news' for Qbiotics is that tumours are proving more challenging. Though for how long?